EDVA — Endovia Health Sciences, Inc.
—
NYSE ·
Consumer Staples ·
Food Products ·
CIK 1553788 ·
Last close
$0.17
Market Cap
—
52W High
$13.40
52W Low
$0.15
ADV30
4,937,779
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | 0 | -2,007,366 | -2,054,787 | 1,076,332 | 242,702 | 16,825,377 |
| Mar 2026 | 4,224 | 1,848 | -978,970 | -2,136,469 | 769,953 | 381,195 | 16,973,235 |
| Dec 2025 | -365,206 | 47,341 | -976,411 | -3,205,257 | 965,694 | 281,435 | 16,266,522 |
| Sep 2025 | 0 | 0 | -9,544,679 | -9,886,045 | 22,489,297 | 265,667 | 15,711,745 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-4,942,824
Investing CF
$0
Financing CF
$5,401,868
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-45.68
As of
2026-08-25
Balance + Analyst (yfinance extras)
Retained Earnings
$-184,411,599
Inventory
$54,922
Receivables
$96,099
ST Investments
—
EBIT TTM
$-19,180,500
Pretax Income TTM
$-22,835,289
Interest Exp TTM
$3,654,789
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 73,066 | -14,186,220 | -25,234,834 | 965,694 | 16,266,522 | -15,300,828 | -4,789,139 |
| Dec 2024 | 801,273 | -9,900,440 | -23,756,551 | 2,760,000 | 21,394,034 | -18,634,849 | -7,795,900 |
| Dec 2023 | 18,850,152 | -15,286,658 | -21,003,757 | 9,900,000 | 15,504,094 | -5,605,326 | -10,189,263 |
| Dec 2022 | 18,087,486 | -21,394,633 | -21,690,469 | 17,304,703 | 7,982,569 | 9,322,134 | -14,073,419 |
TTM Snapshot
Revenues TTM
$-419,526
NetIncome TTM
$-23,720,852
OpCashFlow TTM
—
Assets (Latest)
$769,953
Forward EPS
—
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| KO | COCA COLA CO | $370.75B | $86.17 | — |
| PM | Philip Morris International Inc. | $296.76B | $190.40 | — |
| PEP | PEPSICO INC | $171.72B | $125.71 | — |
| BUD | Anheuser-Busch InBev SA/NV | $132.11B | $75.62 | — |
| BUDFF | Anheuser-Busch InBev SA/NV | $130.14B | $74.49 | — |
News headlines (Yahoo Finance, 1h cache)
Endovia and Lupvindol BioSciences Announce FDA Determination that CannEpil® for Canine Bone Cancer Pain Qualifies as a Minor Use, Establishing Eligibility for Conditional Approval Pathway
2026-10-05 12:45 · Yahoo
Endovia Health Sciences Closes Initial Funding to Accelerate CannEpil® Development Amid Growing Federal Support for Botanical Drug Pathways
2026-09-22 13:30 · Yahoo
Endovia Health Sciences Welcomes Historic Shift in Federal Cannabinoid Policy; Advances CannEpil® FDA Submission and Expands Development Pipeline
2026-08-31 12:30 · Yahoo
Endovia Health Sciences, formerly Splash Beverage, Achieves First FDA Regulatory Milestone for CannEpil® Veterinary Development Program
2026-08-25 12:30 · Yahoo
Splash Beverage Group to Become Endovia Health Sciences; New NYSE American Ticker “EDVA” Effective Monday
2026-08-21 12:38 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.